JBM (Healthcare) Limited provided preliminary unaudited consolidated group earnings guidance for the six months ended 30 September 2022. For the period, the Group expects to record an increase in the range of 110% to 120% in the consolidated profit attributable to Shareholders as compared to that for the six months ended 30 September 2021. The increase in Consolidated Profit was primarily attributable to the easing of social distancing policies in Hong Kong which buttressed retail spending sentiment and a gradual recovery of the Group's overall sales, resulting in a substantial increase in revenue for the six months ended 30 September 2022 alongside a financial subsidy from the government through the Employment Support Scheme.

The trend of consumer-shift towards greater proactivity in managing their health and wellness, together with the aging population, improved living standards and the sedentary lifestyle, will continue to support the growth and are expected to benefit the Group's business in the foreseeable future. The Group has been making sound progress on its cross-border e-commerce platform, which provides a fast expanding avenue for reaching out to those target prospects in the mainland China market.